Claims for Patent: 6,468,757

Summary for Patent: 6,468,757

Title:	Method for determining drug-serum protein binding
Abstract:	The present invention relates to a method of screening for drug binding to serum proteins by: preparing at least two solutions each including a concentration of a serum protein and a concentration of a candidate drug, wherein the concentration of the candidate drug is different for each of the at least two solutions; exposing each of the at least two solutions to a light source; measuring fluorescent emission by the serum protein or a serum protein-candidate drug complex for each of the at least two solutions upon said exposing; and determining whether a change in fluorescence emission is measured for an increased concentration of the candidate drug, wherein the change in fluorescence emission indicates binding of the candidate drug to the serum protein. A kit useful for performing a fluorimetric screening of drug binding to serum proteins is also disclosed.
Inventor(s):	Ramanathan; Murali (Amherst, NY), Morris; Marilyn E. (Amherst, NY)
Assignee:	The Research Foundation of State University of New York (Amherst, NY)
Application Number:	09/767,790
Patent Claims:	1. A method of screening for drug binding to serum proteins, said method comprising: preparing at least two solutions, each of said at least two solutions comprising a concentration of a gerum protein characterized by broad specificity in binding to xenobiotics and a concentration of a candidate drug, wherein the concentration of the candidate drug is different for each of the at least two solutions and, optionally, one of the at least two solutions is a control solution characterized by a candidate drug concentration of zero; exposing each of the at least two solutions to a light source; measuring fluorescent emission by the serum protein or a serum protein-candidate drug complex for each of the at least two solutions upon said exposing; and determining whether a change in fluorescence emission is measured for an increased concentration of the candidate drug, wherein the change in fluorescence emission indicates binding of the candidate drug to the serum protein. 2. The method according to claim 1, wherein said determining further comprises: determining a minimal concentration of the candidate drug to produce a maximal change in fluorescence. 3. The method according to claim 1, wherein the serum protein comprises one or more tryptophan or tyrosine residues. 4. The method according to claim 3, wherein the serum protein is an albumin, a glycoprotein, a lipoprotein, or a combination thereof. 5. The method according to claim 3, wherein the serum protein is human serum albumin or human .alpha..sub.1 -acid glycoprotein. 6. The method according to claim 1, wherein the light source emits light at a wavelength of about 280 nm. 7. The method according to claim 1, wherein said measuring fluorescent emission comprises measuring emission maxima in the range of about 300 nm to about 400 nm. 8. The method according to claim 7, wherein the emission maxima are at a wavelength of about 340 nm. 9. The method according to claim 1, wherein each of the at least two solutions is an aqueous solution. 10. The method according to claim 1, wherein each of the at least two solutions comprises dimethyl sulfoxide (DMSO) as a solvent. 11. The method according to claim 1, further comprising: calculating a dissociation constant (K.sub.d) for the candidate drug and the serum protein. 12. The method according to claim 1, wherein the concentration of the serum protein in each of the at least two solutions is substantially the same. 13. The method according to claim 1, wherein the candidate drug is one of a plurality of candidate drugs, said preparing comprises preparing a series of the at least two solutions for each of the plurality of candidate drugs, said exposing and measuring are carried out in a multiwell format, and said determining is carried out for each of the plurality of candidate drugs. 14. The method according to claim 1, wherein said measuring is specific for a fluorescent emission maxima of unbound serum protein and wherein the change in fluorescent emission by unbound serum protein is a reduction of the fluorescent emission for an increase in candidate drug concentration. 15. The method according to claim 1, wherein said measuring is specific for a fluorescent emission maxima of serum protein bound to the candidate drug and wherein the change in fluorescent emission by the serum protein bound to the candidate drug is an increase of the fluorescent emission for an increase in the candidate drug concentration. 16. A method of screening for drug binding to serum proteins, said method comprising: preparing at least two solutions, each of said at least two solutions comprising a concentration of a serum protein characterized by broad specificity in binding to xenobiotics and a concentration of a candidate drug, wherein the concentration of the candidate drug is different for each of the at least two solutions and, optionally, one of the at least two solutions is a control solution characterized by a candidate drug concentration of zero; exposing each of the at least two solutions to a light source; measuring fluorescent emission by the serum protein or a serum protein-candidate drug complex for each of the at least two solutions upon said exposing; and calculating a dissociation constant (K.sub.d) for the candidate drug and the serum protein based on the measured fluorescence emissions. 17. The method according to claim 16, wherein the serum protein comprises one or more tryptophan or tyrosine residues. 18. The method according to claim 17, wherein the serum protein is an albumin, a glycoprotein, a lipoprotein, or a combination thereof. 19. The method according to claim 17, wherein the serum protein human serum albumin or human .alpha..sub.1 -acid glycoprotein. 20. The method according to claim 16, wherein the light source its light at a wavelength of about 280 nm. 21. The method according to claim 16, wherein said measuring fluorescent emission comprises measuring emissions in the range of about 300 nm to about 400 nm. 22. The method according to claim 21, wherein the emissions are at a wavelength of about 340 nm. 23. The method according to claim 16, wherein each of the at least two solutions is an aqueous solution. 24. The method according to claim 16, wherein each of the at least two solutions comprises dimethyl sulfoxide (DMSO) as a solvent. 25. The method according to claim 16, wherein the concentration of the serum protein in each of the at least two solutions is substantially the same. 26. The method according to claim 16, wherein the candidate drug is one of a plurality of candidate drugs, said preparing comprises preparing a series of the at least two solutions for each of the plurality of candidate drugs, said exposing and measuring are carried out in a multiwell format, and said determining is carried out for each of the plurality of candidate drugs. 27. A kit useful for performing a fluorimetric screening of drug binding to serum proteins, the kit comprising: a plurality of detection cells compatible for use with a fluorimetric device; one or more solutions each comprising a predetermined concentration of a serum protein characterized by broad specificity in binding to xenobiotics; and instructions for combining a volume of the one or more solutions with a quantity of a drug in the detection cells, exposing the detection cells to the fluorimetric device, and analyzing fluorimetric emission data. 28. The kit according to claim 27, wherein the detection cells are cuvettes. 29. The kit according to claim 27, wherein the detection cells are multiwell plates. 30. The kit according to claim 27, wherein the serum protein comprises one or more tryptophan or tyrosine residues. 31. The kit according to claim 30, wherein the serum protein is an albumin, a glycoprotein, a lipoprotein, or a combination thereof. 32. The kit according to claim 30, wherein the serum protein is human serum albumin or human .alpha..sub.1 -acid glycoprotein.

Details for Patent 6,468,757

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2020-01-25
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2020-01-25
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2020-01-25